SPOTLIGHT: Isolagen modifies trial in response to FDA


In order to clarify protocol issues and questions raised by the FDA, Isolagen says it will modify its ongoing late-stage trial of Isolagen Therapy for acne scars and make it a Phase II/III trial. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.